Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

For income investors, there are numerous dividend stocks with strong records, stability and growth potential that can generate wealth for you in the long term.

These five high-yield stocks are drawing investor interest in February, offering above-average dividends backed by cash flow ...

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

These funds both pay more than 3% and have been beating the market this year.

Lastly, Pfizer is an attractive dividend stock, with a juicy current yield of 6.7%. Long-term, income-seeking investors who initiate positions today might see significant upside from strong upcoming ...

Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors.

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted ...

Whether you’re enjoying your retirement or still planning for your golden years, generating a steady source of monthly income ...

We've all heard the stories. $100 invested in shares of P&G in 1932 would now be worth over $1 million! But if that's true, why is the Dow, which started in 1896, only at a level of 50,000, which it ...